Effects of alendronate and denosumab on glucocorticoid-induced osteoporosis by a randomized, open-labeled study

INTERVENTION: alendronate 35mg/week +alfacalcidol 0.5ug/day. It continues as glucocorticoid‐induced osteoporosis treatment. denosumab 60mg/6months +alfacalcidol 0.5ug/day. It continues as glucocorticoid‐induced osteoporosis treatment. CONDITION: Glucocorticoid‐induced osteoporosis PRIMARY OUTCOME: Percent change in bone mineral density of the lumber spine and femoral neck SECONDARY OUTCOME: Incident vertebral fracture and non‐vertebral fracture; safety; bone makers INCLUSION CRITERIA: Guideline on the management and treatment of glucocorticoid‐induced osteoporosis of the Japanese Society (2014) with adaptation patients.